No Data
No Data
The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 26%
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
William Blair Keeps Their Hold Rating on FibroGen (FGEN)
FibroGen Down on Peer-Review Publication
FibroGen Announces Publication Of Results From Phase 1 Monotherapy Study Of FG-3246 In Patients With Metastatic Castration-Resistant Prostate Cancer In Journal of Clinical Oncology; Says Initiation Of Phase 2 Monotherapy Dose Optimization Study Of...
Express News | FibroGen Announces Publication of Results From Phase 1 Monotherapy Study of FG-3246 in Patients With Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology